- Group sales grew by 6%1 at constant exchange rates (CER) (2% in CHF) in the first nine months, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8%
|
- In the third quarter, Group sales rose by 9% (6% in CHF), as they did in the second quarter
|
- Pharmaceuticals Division sales rose by 7% in the first nine months; the strong growth of 9% in the base business2 was driven by continued high demand for our newer medicines to treat severe diseases; Vabysmo (serious eye diseases), Phesgo (breast cancer) and Ocrevus (multiple sclerosis) were major growth drivers
|
- Diagnostics Division sales increased by 5% in the first nine months, while the base business2 grew by 8% due to higher demand for immunodiagnostic, pathology and molecular solutions
|
|
|
-
- US approval for Itovebi (inavolisib) for breast cancer, Ocrevus Zunovo subcutaneous injection for multiple sclerosis and Tecentriq Hybreza subcutaneous formulation for various types of cancer
|
-
- EU approval for Vabysmo for retinal vein occlusion (RVO), a serious eye disease, and PiaSky for paroxysmal nocturnal haemoglobinuria (PNH), a rare life-threatening blood condition
|
-
- Positive phase III data for Gazyva/Gazyvaro (lupus nephritis, a kidney disease), Xofluza (influenza) and Tecentriq (lung cancer). New positive phase II data for fenebrutinib (multiple sclerosis), and new positive long-term data for Evrysdi (spinal muscular atrophy)
|
-
- Acquired AntlerA Therapeutics for a novel target in ophthalmology, and signed an agreement for the acquisition of two next-generation CDK inhibitor drugs targeting breast cancer from Regor Pharmaceuticals
|
-
- Closing of the acquisition of LumiraDx’s point-of-care technology to expand access to diagnostic testing in primary care and low- and middle-income countries
|
-
- Launch of the cobas Respiratory flex test, the first to use our new Temperature-Activated Generation of Signal (TAGS) technology
|
-
- WHO endorsement for CINtec PLUS testing for cervical cancer prevention
|
- Outlook for 2024 confirmed
|
| Roche CEO Thomas Schinecker: “Our strong growth momentum continued in the third quarter, reflecting the high demand for our innovative medicines and diagnostic solutions and their positive impact on patients’ lives around the world. |
| We made significant progress in our pharmaceuticals portfolio in the last quarter with five important regulatory approvals for our medicines, three positive phase III read-outs, and two acquisitions to strengthen our oncology and ophthalmology pipelines. |
| Itovebi (inavolisib) recently received US approval based on clinical data demonstrating a reduction of more than 50% in the risk of death or worsening disease for people suffering from a form of advanced, hard-to-treat breast cancer. In addition, we had positive phase III results for Gazyva/Gazyvaro in lupus nephritis, a potentially life-threatening kidney disease for which limited treatment options are available today. |
| We confirm our outlook for 2024.” |
| Sales |
CHF millions |
As % of sales |
% change |
| January‒September |
2024 |
2023 |
2024 |
2023 |
At CER |
In CHF |
| Group |
44,984 |
44,053 |
100.0 |
100.0 |
6 |
2 |
| Pharmaceuticals Division |
34,257 |
33,372 |
76.2 |
75.8 |
7 |
3 |
| United States |
18,166 |
17,430 |
40.4 |
39.6 |
7 |
4 |
| Europe |
6,613 |
6,259 |
14.7 |
14.2 |
7 |
6 |
| Japan |
2,083 |
2,937 |
4.6 |
6.7 |
-21 |
-29 |
| International* |
7,395 |
6,746 |
16.5 |
15.3 |
19 |
10 |
| Diagnostics Division |
10,727 |
10,681 |
23.8 |
24.2 |
5 |
0 |
All figures shown in the table were restated to reflect the shift of the Foundation Medicine (FMI) business from the Pharmaceuticals Division to the Diagnostics Division.
*Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, and others |
| Outlook for 2024 confirmed.
Roche expects an increase in Group sales in the mid-single-digit range (CER). |
| Core earnings per share are targeted to grow in the high single-digit range (CER), excluding the impact of the resolution of tax disputes in 2023. |
| Roche expects to further increase its dividend in Swiss francs. |
| For the full document click the link below: |
| Roche |
| Stay ahead of the curve! Subscribe to InsidEntity for daily updates on all your favourite companies. |
